Moderna CEO Files to Sell $5M in Stock
- ByInvesting.com-
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Moderna Inc (MRNA)
123.64
-0.68(-0.55%)
Pre Market
123.30
-0.34(-0.27%)
- Real-time Data
- Volume:3,942,637
- Day's Range:121.25 - 125.01
- 52 wk Range:115.61 - 434.00
MRNA Overview
- Prev. Close
- 124.32
- Day's Range
- 121.25-125.01
- Revenue
- 22.6B
- Open
- 122.81
- 52 wk Range
- 115.61-434
- EPS
- 34.96
- Volume
- 3,942,637
- Market Cap
- 48.37B
- Dividend (Yield)
- N/A(N/A)
- Average Volume (3m)
- 4,873,691
- P/E Ratio
- 4.24
- Beta
- 1.6
- 1-Year Change
- -71.26%
- Shares Outstanding
- 391,199,544
- Next Earnings Date
- 02 Nov 2022
What is your sentiment on Moderna?
or
Market is currently closed. Voting is open during market hours.
Moderna Inc News
- 1 CEO Buy and 2 CEO Sells of Interest Today
- ByInvesting.com-
By Davit Kirakosyan Insider buying and selling activities are important for investors to pay attention to. While insiders sell for many reasons, including taxes, it doesn’t always...
- Midday Movers: Twilio, Starbucks, Moderna and More
- ByInvesting.com-
By Liz Moyer Investing.com -- U.S. stocks were bouncing back slightly from Tuesday's rout. Here are the midday movers for Sept. 14: Twilio Inc (NYSE:TWLO) stock rose 12% after the...
Moderna Inc Analysis
- For Moderna, Valuation Still A Question Mark
MRNA is an exceptionally difficult stock to value, given enormous uncertainty surrounding its COVID-19 vaccine and other drugs in its pipeline But there is a case that an...
- Moderna: Stock's Long-Term Appeal Goes Beyond COVID-19 Pandemic
The steep plunge in Moderna stock comes amid signs that the pandemic is moving towards an endemic stage The company still maintains a strong sales pipeline for its COVID vaccines,...
- Oil’s Iran Cliffhanger: What To Know And What To Expect
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Moderna Inc Company Profile
Moderna Inc Company Profile
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Read More
Analyst Price Target
| Average | 219.33 (+77.40% Upside) |
| High | 506 |
| Low | 70 |
| Price | 123.64 |
| No. of Analysts | 15 |
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Analysts 12-Month Price Target
Technical Summary
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Neutral | Sell | Strong Sell | Sell |
| Technical Indicators | Strong Buy | Buy | Strong Sell | Strong Sell | Strong Sell |
| Summary | Strong Buy | Neutral | Strong Sell | Strong Sell | Strong Sell |
Trending Stocks
Trending Stocks
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 6.88 | 7.14 | 6.865 | -0.540 | -7.28% | 17.90M | Sydney | |||
| 0.034 | 0.039 | 0.034 | -0.005 | -12.82% | 32.12M | Sydney | |||
| 36.20 | 37.18 | 36.20 | -1.970 | -5.16% | 15.29M | Sydney | |||
| 0.935 | 0.935 | 0.91 | -0.005 | -0.53% | 11.20M | Sydney | |||
| 15.94 | 16.38 | 15.84 | -0.820 | -4.89% | 10.27M | Sydney | |||
| 4.14 | 4.19 | 4.03 | +0.050 | +1.22% | 4.31M | Sydney | |||
| 0.70 | 0.73 | 0.67 | +0.01 | +1.45% | 5.34M | Sydney | |||
| 3.62 | 3.74 | 3.62 | -0.260 | -6.70% | 4.91M | Sydney | |||
| 1.54 | 1.57 | 1.51 | -0.07 | -4.04% | 70.45K | Sydney | |||
| 7.39 | 7.62 | 7.39 | -0.470 | -5.98% | 6.28M | Sydney | |||
| 30.20 | 30.42 | 29.55 | -1.580 | -4.97% | 11.50M | Sydney | |||
| 31.10 | 31.35 | 29.48 | +0.21 | +0.68% | 1.19M | Sydney | |||
| 13.59 | 14.25 | 13.59 | -1.110 | -7.55% | 4.89M | Sydney | |||
| 3.39 | 3.435 | 3.30 | +0.030 | +0.89% | 2.76M | Sydney | |||
| 0.18 | 0.19 | 0.175 | -0.010 | -5.26% | 26.42M | Sydney |